Low Peripheral Blood B Lymphocyte Count Predict Poor Outcome in Patients with Multiple Myeloma

Yuqi Wang,Zhongxin Zheng,Qiaoxi Kang,Linjing Cai,Shanshan Zhang,Huan Chen,Youhai Yuan,Hanzhen Zhang,Xiaolei Wei,Ru Feng,Yongqiang Wei

DOI: https://doi.org/10.21203/rs.3.rs-5358538/v1

2024-01-01

Abstract:Previous evidence suggested that B lymphocyte may involve in the progression and prognosis of multiple myeloma (MM). However, the prognostic value of peripheral B lymphocyte counts on MM before and after treatment in the novel agent era was rare reported. Herein, we conducted a retrospective study in our center to detect peripheral B lymphocyte counts by flow cytometry in 110 patients with MM at our center and explore the relation with survival. The B lymphocyte count was significantly lower in MM patients than healthy controls (p < 0.005). The cutoff value of B lymphocyte count at diagnosis was 49/µl in MM and 94 patients divided into in high B lymphocyte group. Patients with low B lymphocyte count had a significant shorter progression-free survival (PFS) (p = 0.025) and a trend of unfavorable overall survival (OS) (p = 0.053) at diagnosis and after 4 cycles’ induction treatments. Furthermore, Multivariate analysis showed that low B lymphocyte count at diagnosis independent of ISS stage was a significantly inferior marker for predicting PFS (p = 0.027, hazard ratio(HR) 2.281, 95% confidence interval (CI) 1.098–4.741) and a trend for OS (p = 0.083, HR 2.394, 95% CI 0.896–6.160). In summary, these results suggested the low B lymphocyte count was associated with poor outcome in MM patients at diagnosis and after treatment in the novel agent era.